Lipocine (LPCN) Amortizatization of Intangibles (2015 - 2025)
Lipocine's (LPCN) quarterly Amortizatization of Intangibles came in at $33908.0 in Q3 2025, down 79.83% YoY from $168145.0 in Q3 2024, and down 1.48% on a QoQ basis from $34416.0 in Q2 2025.
Lipocine (LPCN) Amortizatization of Intangibles (2015 - 2025) Analysis & Trends
Lipocine (LPCN) has 11 years of Amortizatization of Intangibles data on file, last reported at $33908.0 in Q3 2025.
- Quarterly Amortizatization of Intangibles fell 79.83% year-over-year to $33908.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $245108.0 (down 68.65% YoY) and the FY2024 annual result came in at $697865.0, down 26.74% from the prior year.
- Amortizatization of Intangibles retreated to $33908.0 in Q3 2025, from $34416.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $254215.0 in Q1 2023 to a low of -$156618.0 in Q4 2021.
- A 5-year average of $72816.8 and a median of $58209.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2021 — Amortizatization of Intangibles slumped 805.45% — and 2023, when it jumped 806.14%.
- Tracing LPCN's Amortizatization of Intangibles over 5 years: stood at -$156618.0 in 2021, then jumped by 201.54% to $159036.0 in 2022, then advanced by 27.37% to $202559.0 in 2023, then sank by 41.46% to $118575.0 in 2024, then tumbled by 71.4% to $33908.0 in 2025.
- The last three Amortizatization of Intangibles figures came in at $33908.0 (Q3 2025), $34416.0 (Q2 2025), and $58209.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 33,908.00 |
| Sep 30, 2025 | 33,908.00 |
| Jun 30, 2025 | 34,416.00 |
| Jun 30, 2025 | 34,416.00 |
| Mar 31, 2025 | 58,209.00 |
| Mar 31, 2025 | 58,209.00 |
| Dec 31, 2024 | 118,575.00 |
| Dec 31, 2024 | 118,575.00 |
| Sep 30, 2024 | 168,145.00 |
| Sep 30, 2024 | 168,145.00 |
| Jun 30, 2024 | 196,249.00 |
| Jun 30, 2024 | 196,249.00 |
| Mar 31, 2024 | 214,896.00 |
| Mar 31, 2024 | 214,896.00 |
| Dec 31, 2023 | 202,559.00 |
| Dec 31, 2023 | 202,559.00 |
| Sep 30, 2023 | 241,667.00 |
| Sep 30, 2023 | 241,667.00 |
| Jun 30, 2023 | 254,210.00 |
| Jun 30, 2023 | 254,210.00 |